drugset / Trial / NCT04853823
A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.
Timeline
- Start
- 2021-11-01
- Primary completion
- 2022-11-01
- Completion
- 2022-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PDC-APB | Unknown | 5 mg | Intramuscular |
| Subject | PDC-APB | Unknown | 10 mg | Intramuscular |
| Subject | PDC-APB | Unknown | 15 mg | Intramuscular |
| Subject | PDC-APB | Unknown | 20 mg | Intramuscular |